Protective effect of resveratrol on agonist-dependent regulation of vascular contractility via inhibition of rho-kinase activity.
The present study was undertaken to investigate the influence of resveratrol on vascular smooth muscle contractility and to determine the mechanism involved. Denuded aortic rings from male rats were used and isometric contractions were recorded and combined with molecular experiments. Resveratrol at a low concentration (0.03 mmol/l) relaxed directly and more markedly fluoride-induced vascular contraction than phorbol ester-induced contraction. Furthermore, resveratrol more markedly inhibited fluoride-induced increases in pMYPT1 levels than phorbol ester-induced increases. It also more markedly inhibited fluoride-induced increases in pMYPT1 levels than pERK1/2 levels, suggesting that the mechanism involved the inhibition of Rho-kinase activity and the subsequent phosphorylation of MYPT1. This study provides evidence regarding the mechanism underlying the relaxation effect of resveratrol on agonist-induced vascular contraction regardless of endothelial function.
Je
Hyun Dong
HD
Department of Pharmacology, College of Pharmacy, Catholic University of Daegu, Gyeongbuk, Korea.
Lee
Myeong Hwan
MH
Jeong
Ji Hoon
JH
Park
Sun Young
SY
Sohn
Uy Dong
UD
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000201:enzymology; D015153:Blotting, Western; D002118:Calcium / Q000378:metabolism; D020536:Enzyme Activators / Q000494:pharmacology; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects* / Q000502:physiology; D010703:Phorbol Esters / Q000494:pharmacology; D010766:Phosphorylation; D011189:Potassium Chloride / Q000494:pharmacology; D054645:Protein Phosphatase 1 / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D012969:Sodium Fluoride / Q000494:pharmacology; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D020536:Enzyme Activators; D010703:Phorbol Esters; D013267:Stilbenes; D014665:Vasodilator Agents; D011189:Potassium Chloride; D012969:Sodium Fluoride; D054460:rho-Associated Kinases; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; C499850:Ppp1r12a protein, rat; D054645:Protein Phosphatase 1; D000077185:Resveratrol; D002118:Calcium